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Specific CD44 isoforms, intercellular adhesion molecule-1, uroki-
nase-type plasminogen activator and its receptor (uPA/uPAR) and
aminopeptidase N (APN/CD13) are functionally important cell
surface proteins involved in invasive and metastatic behaviour of
tumour cells. At least 2 categories of proteins are responsible for
invasion and metastasis: adhesion molecules and proteolytic
enzymes. Adhesion proteins, as CD44(var) and ICAM-1 mediate
cell–cell and cell–matrix interactions and proteases activate proen-
zymes or initiate whole proteolytic cascades resulting in the
hydrolysis of extracellular matrix (ECM) and protein components
of basement membranes. Among the tumour-associated pro-
teinases and peptidases uPA and APN play a crucial role (Saiki 
et al, 1993; Riemann et al, 1995; Swiercz et al, 1998). Besides the
primary biological function of uPA to catalyse the activation of
plasminogen to plasmin this serine protease has a multifunctional
potential. Associated with its receptor and the endogenous plas-
minogen activator inhibitor-type-1 (PAI-1) the following biolog-
ical effects are described: (1) growth factor-like function, (2)
mediation of cell adhesion and (3) signal-transduction function
(Andreasen et al, 1997; Nguyen et al, 1998). 
Compared to proteolytic enzymes which are secreted (i.e.
released) in active or inactive form from the tumour cell into the
ECM, this study was focused on membrane-bound proteases since
they should be more effective with respect to invasion (Evans,
1991; Meissauer et al, 1992). It is generally suggested that proteases
bound on the cell surface offer a more versatile and efficient attack
on ECM in contrast to proteases that are released from the cell. 
The aim of the present study was to analyse renal cell carcinoma
(RCC) cells regarding the cell surface antigens mentioned above
avoiding disadvantages of other methods (e.g. immunofluores-
cence: cellular autofluorescence). 
Unlike CD44 variant sequences, ICAM-1 and uPAR – exclu-
sively detected by immunoluminescence – uPA and APN were
additionally characterized by enzyme activity assays. In contrast
to tests of cell extracts or tissue homogenates by ELISA that can
not differentiate between intracellular and extracellular antigen
localization the immunological technique described here for intact
cells enables one to detect the existence and extent of proteins on
the cell surface (Laube, 1999a). Additionally, activity assays of
vital tumour cells result in values for the specific proteolytic
capacity that can be attributed to the tumour cell itself. This
enzyme activity detected in cell suspensions or monolayers is not
interfered by intracellular tumour enzymes or enzymes associated
with or secreted from surrounding non-tumour cells as it is the
case in tissue homogenates however. 
MATERIALS AND METHODS 
Cell lines 
The human RCC cell lines 49RC 43STR and 75RC 2STR were
originally provided by G Mickisch (Rotterdam, The Netherlands).
Cells were cultured in RPMI 1640 medium containing NaHCO3
(Biochrom, Berlin, Germany) and supplemented with L-glutamine,
penicillin, streptomycin (Sigma, Deisenhofen, Germany) and 10%
fetal calf serum (FCS) (CCPro, Neustadt/W, Germany). Cultures
were maintained at 37˚C in a 5% CO2 atmosphere. In order to
obtain cell suspensions for the labelling of cell surface proteins
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standard culture flasks were used. To obtain cell monolayers, Petri
dishes (diameter 35 mm, Greiner, Frickenhausen, Germany) were
used for evaluation of the enzyme activity by HPLC. 
Antibodies 
All monoclonal antibodies (mAbs) were of the IgG 1 type. The
anti-CD44 mAbs were directed against the variable portion of the
molecule: anti-CD44(v5), (VFF-8); anti-CD44(v6), (VFF-18);
anti-CD44(v7), (VFF-9); polyclonal Ab: goat-anti-CD44(v3-v10)
(Bender Med Systems, Vienna, Austria); anti-uPA (IM13L), anti-
uPA(IM14L), anti-uPAR (GR35), anti-CD54 (15.2) (Calbiochem-
Novabiochem, Bad Soden, Germany); anti-CD54 (HA58),
anti-CD13 (WM15) (Pharmingen, Hamburg, Germany); anti-
CD13 (SJ1D1) (Coulter-Immunotech, Marseille, France); conju-
gates: anti-mouse-IgG (Fab)-HRP and anti-sheep/goat-IgG
(Fab)-HRP (Boehringer Mannheim, Germany). Normal mouse-
IgG 1 (Sigma, Deisenhofen, Germany) and normal goat-IgG
(Boehringer Ingelheim, Germany) were used for blocking and
negative controls. 
Reagents 
Luminol (3-aminophthalhydrazide), phenylmethylsulfonyl fluo-
ride (PMSF) (Boehringer Mannheim, Germany); 6-hydroxy-
benzothiazole, plasminogen (from human plasma, P-5661),
1,10-phenanthroline, phosphatidylinositol-specific phospholipase
C (PI-PLC) (Sigma, Deisenhofen, Germany); PI-PLC (recombi-
nant, GPI-02) (Oxford GlycoSystems, UK); Z-Gly-Gly-Arg-AMC
(urokinase substrate III), D-Val-Phe-Lys-CMK (chloro-methylke-
tone) (Calbiochem-Novabiochem, Bad Soden, Germany); H-Ala-
pNA (Bachem, Heidelberg, Germany). 
Cell labelling 
Cells were grown to near confluence, harvested with
EDTA/trypsin and washed with 0.01 M phosphate-buffered saline
(PBS) pH 7.4. To reconstitute cell surface proteins, cells were
resuspended and maintained in RPMI medium. Cells were washed
thoroughly and incubated in PBS with normal goat-IgG (for the
detection with specific mAbs) or normal mouse-IgG 1 (for the
detection with the polyclonal goat-Ab) to block IgG and Fc recep-
tors. Cells were washed and incubated with appropriate dilutions
of the various Abs (Ab concentration generally used: 10 µ g ml–1;
60 min, 4˚C, with shaking) followed by washing the cells twice.
Then, cells were incubated with the corresponding conjugate
(45 min, 4˚C, with shaking) and after washing 3 times the cells
were subjected to the luminescent test. 
Luminescence 
Aliquots of cell suspension (100 µ l, 5 × 105–1 × 106 cells) were
mixed with 200 µ l substrate solution (PBS, pH 7.5;
luminol/H2O2/6-hydroxybenzothiazole) (Kricka and Thorpe,
1990) and the light emission was measured as intensity (relative
light units: RLU s–1) 30 s after the initiation. 
Enzyme activities 
uPA-activity assay 
(1) Endogenous membrane-bound uPA activity was assayed as
described (Zimmerman et al, 1978) with modifications: the reaction
was started by adding 100 µ l of a cell suspension (2 × 106 cells) to
1 ml substrate solution (Z-Gly-Gly-Arg-AMC, final concentration
0.15 mM in PBS) with or without inhibitor (D-Val-Phe-Lys-CMK,
PMSF). Excitation and emission wavelengths were set at 380 nm
and 450 nm, respectively. The fluorescence of AMC released was
monitored continuously over a period of 5 min. Values for the
maximal velocity (∆ RFU min–1) were used for calculations. (2) An
indirect assay for uPA activity was performed by release of
plasmin from plasminogen (PG) after preincubation of cells with
PG (final concentration 0.5 U ml–1; 10 min, 37˚C) using the same
procedure as described under (1). 
APN-activity assay 
Tests were performed with intact cells freshly harvested and
washed thoroughly. After 45 min preincubation of cells (2 ×
106/0.5 ml PBS, pH 7.4) in the presence or absence of different
effectors (inhibitors: 1,10-phenanthroline, ethylenediamine-
tetraacetic-acid-Na2-salt (EDTA): 25˚C, Abs: 4˚C) 0.5 ml
substrate solution was added (final concentration of Ala-pNA:
1.5 mM in PBS). Cells were allowed to react 20–30 min at 37˚C
with gentle shaking. The amount of p-nitroaniline formed was
measured in the supernatant by reading the absorbance at 405 nm.
Each test was run in duplicate. 
High-pressure liquid chromatography (HPLC) 
Cell monolayers grown in Petri dishes were used for uPA activity
and inhibition assays (seeding: 1 × 105 cells/Petri dish in 2 ml
medium; cultivation: 24 h in RPMI and additionally 24 h in RPMI
without FCS; cell monolayers were rinsed thoroughly with PBS
and subjected to the test). Endogenous membrane-bound uPA
activity was assessed using the substrate Z-Gly-Gly-Arg-AMC
(final concentration: 0.15 mM in PBS, 37˚C, reaction interval:
0–60 min). For kinetic analysis aliquots of the reactive supernatant
from cell monolayers were collected, quickly frozen at –20˚C, and
subsequently separated on a HPLC column. Column: Nucleosil
120/5, C-18, Macherey & Nagel, Germany); solvent system:
acetonitrile/H2O = 60/40; λ Ex = 340 nm, λ Em = 440 nm. Recording:
8450 Fluorescence HPLC-Monitor (Bischoff, Germany). The
increase of AMC released by the reaction was calculated with a
software program (Euro-Chrom 2000 – Integration package,
Knauer, Germany) using the peak area. 
Instrumentation 
Luminescent detection was performed with the luminometer
Lumat LB 9501 (Berthold, Germany), the fluorescent measure-
ment in cell suspensions with the spectrophotometer F-2000
(Hitachi, Japan), and the colorimetric assay using the Zeiss
spectrophotometer Spekol UV-VIS 3.01. 
Cell viability was assessed by exclusion of trypan blue. 
RESULTS 
Two human RCC cell lines were investigated for the expression of
different tumour-specific cell surface proteins. Results obtained by
immunolabelling are shown in Figure 1A–C. Due to more binding
sites the polyclonal Ab to CD44(v3-v10) gave the most intensive
signal. Only the cell line 75RC 2STR exhibited a strong reaction
with anti-CD44(v6) and none of the cell lines displayed a distinct
reaction with anti-CD44(v5) or antiCD44(v7). These results were
reproducible and independent from culture stage and cell number. 
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Figure 1B shows the detection of uPA with 2 different mAbs
compared to the signal intensity received for CD44(v6) in this
series. In many labelling experiments anti-CD44(v6) was used as
an internal control. The signal intensity for CD44(v6) of about
3000 RLU/s (49RC 43STR) is very low and not significant. The
anti-uPA (IM13L) antibody recognizes an epitope on the B-chain
which contains the catalytic active site of the molecule. The anti-
uPA (IM14L) antibody recognizes an epitope in the amino terminal
region of the A-chain. With identical Ab concentrations the anti-uPA
(IM14L) antibody always exhibited a distinctly stronger signal
compared to anti-uPA (IM13L) antibody. For both anti-uPA anti-
bodies signal intensities were found to depend on the concentrations
used (1 = 10 µ g ml–1 and 2 = 2 µ g ml–1, respectively). 
Figure 1C demonstrates the immunological response obtained
for ICAM-1, APN (CD13) and uPAR. Contrary to the level of
uPAR that is nearly equal for both cell lines, the expression of
ICAM-1 and APN is much different. While 49RC 43STR exhibit a
high level of APN and a low level of ICAM-1, in the cell line
75RC 2STR for these 2 antigens an inverse proportion is observed. 
In order to test partially the specific proteolytic capacity that can
be attributed to the tumour cell itself, the activity of 2 typical
proteases, uPA and APN, was investigated. Figure 2 shows a first
approach to use intact cells for enzymatic assays. Using cell
suspensions the uPA activity was measured directly with the fluo-
rogenic urokinase substrate Z-Gly-Gly-Arg-AMC as well as indi-
rectly via plasmin generated from human plasminogen. Details see
under uPA activity assay, method (1) and (2), respectively.
Because both uPA and plasmin are serine proteases with similar
specificity the substrate Z-Gly-Gly-Arg-AMC was used for the
detection of both proteases. For the cell line 49RC 43STR it was
found that addition of plasminogen to a cell suspension results in
an activity increase by 65% but the 75RC 2STR cells gave only an
increase of about 10%. As Figure 2 clearly shows the activator
activity as well as plasmin activity are inhibited by PMSF and the
CMK-inhibitor (inhibition of uPA plus plasmin by PMSF is not
shown). Because of the very low uPA expression by 75RC 2STR
the activator activity and the plasmin activity of these cells are
completely inhibited by D-Val-Phe-Lys-CMK. 
Since the cell line 49RC 43STR showed the stronger immuno-
logical response and the higher activity level for uPA compared to
75RC 2STR, the former cells were used to test the uPA activity in
cell monolayers grown in Petri dishes (Figure 3). Aside from the
partial inhibition by PMSF and the CMK-inhibitor the uPA
activity was markedly inhibited following the preincubation with
specific Abs to uPA (B-chain) and uPAR. Both Abs reduce the uPA
activity in a concentration-dependent manner. But the Ab to an
epitope on the B-chain, bearing the active site, diminishes the
activity to a higher degree than the Ab to the receptor. Using
mouse non-immune IgG 1 as control the uPA activity was
decreased negligible. Because of the GPI anchor-bound uPAR PI-
PLC was used to release the uPA/uPAR complex from the cell.
However, the uPA activity of PI-PLC-pretreated cells was
decreased only 10–15%. Possible reasons for the hindered accessi-
bility of the anchor-bound receptor will be discussed below. 
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Figure 1 (A–C) Immunoluminescent detection of cell surface antigens in
the renal cell carcinoma cell lines 75RC 2STR and 49RC 43STR. Values for
the non-specific binding were subtracted. (A) Detection of CD44 variant
sequences. (B) Detection of uPA in comparison with CD44(v6). The signal
intensity for CD44(v6) of about 3000 RLU s–1 (cell line 49RC 43 STR) is very
low and not significant. 13: anti-uPA (IM13L) recognizes an epitope on the 
B-chain of uPA. 14: anti-uPA (IM14L) recognizes an epitope on the A-chain of
uPA. 1: Ab concentration 10 µ gm l –1; 2: Ab concentration 2 µ gm l –1. 
(C) Detection of ICAM-1/CD54, APN/CD13 and uPAR/CD87. (A): anti-CD54
(15.2), (B): anti-CD54 (HA58), (C): anti-CD13 (SJ1D1), (D): anti-CD13
(WM15), (E): anti-uPAR (GR35) 
Figure 2 uPA activity determined by method (1) and (2), respectively.
Contr.: without inhibitor; PG: plasminogen; PG+CMK: inhibited enzyme
activity assay following preincubation of cells with PG. CMK (D-Val-Phe-Lys-
CMK) and PMSF were used in a final concentration of 0.1 mM. For further
details see under Materials and methods 
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On the other hand it could be shown by a brief treatment (30 s)
of cells with glycine buffer, pH, 3, 0 (Cubellis et al, 1990;
Mohanam et al, 1993; Hoyer-Hansen et al, 1997) that the uPA
activity was decreased to 68.2% in 75RC 2STR and to 33% in
49RC 43STR cells due to the removal of uPA from the receptor
(results not shown). 
In spite of the lower level of APN based on the immunological
result (Figure 1C) the cell line 75RC 2STR was used for the
activity assay because of the more moderate enzyme activity
(Figure 4). In the cell line 49RC 43STR APN is overexpressed and
therefore the intense reactivity of a given cell number is not
favourable to observe distinct inhibition effects. From the
numerous inhibitors suitable for the metalloprotease APN (Zn2+-
dependent), 1,10-phenanthroline and EDTA were employed. Both
inhibitors decrease the APN activity in a concentration-dependent
fashion, but, despite lower concentrations used, 1,10-phenanthroline
to a higher degree than EDTA. Further it was shown that both mAbs
(up to a concentration of 20 µ g ml–1) used for the detection of APN
only caused an inhibitory effect of about 15% (results not shown). 
DISCUSSION 
This investigation was performed in order to characterize 2 RCC
cell lines by immunological labelling as well as enzyme activity
assays. For that purpose several cell surface antigens with close
relations to cell–cell and cell–matrix adhesion and ECM break-
down were selected: CD44 isoforms, ICAM-1, uPA/uPAR and
APN. 
So far, numerous investigations of cell surface proteins were
performed by immunofluorescent methods (e.g. flow cytometry)
or immunohistochemistry. Previous experiments have shown that
cell surface proteins can also be detected by immunoluminescence
(Laube, 1996; Lischke et al, 1996; Laube and Göhring, 1997).
This contribution describes the application of immunolumines-
cence for the detection of surface antigens mentioned above on
intact cells. It is possible to use this advantageous technique as an
alternative method to immunofluorescent labelling. The immuno-
luminescent technique is reproducible and very sensitive. After
immunolabelling of cells using horseradish peroxidase (HRP) as
marker enzyme for the first or second Ab this method enables
both luminescent and fluorescent measurements. HRP
substrates are available to produce luminescence (luminol) or
fluorescence (3-(p-hydroxyphenyl) propionic acid and 10-acetyl-
3,7-dihydroxyphenoxazine), (Laube, 1999a). Many applications
of immunoassays associated with chemiluminescence are
described but only few contributions have been published
concerning the detection of cell surface proteins of viable cells.
Indeed, immunoluminescence is based on a similar procedure as
immunofluorescence, but the former has some advantages: there is
no need for fluorochrome conjugates (fluorochrome-labelled
Abs), light excitation is not required, that means photobleaching
and cellular autofluorescence do not occur (non-transfected
mammalian cells do not produce bioluminescence), simple control
to check cells for endogenous peroxidase-like proteins that would
interfere with the test, and easy measurement with a low-cost tube
luminometer compared to an expensive flow cytometer. 
This contribution has shown that all 5 membrane-bound anti-
gens are expressed to a different degree in the 2 RCC cell lines.
The activity assays, additionally performed to immunolumines-
cent labelling, enabled us to confirm the individual immunological
signal intensity: a low immunological response of a given antigen
(protease) conformed with a moderate to little enzyme activity.
Unlike 75RC 2STR the cell line 49RC 43STR expressed high
levels of APN and uPA. Contrary to that the cell line 75RC 2STR
expressed high levels of ICAM-1 and CD44(v6), whereas 49RC
43STR showed a low level of ICAM-1 and no distinct light signal
with anti-CD44(v6). 
A comparison of different tumours demonstrates distinct varia-
tions in the CD44 isoform expression profile. Reasons for incon-
sistent results even within the RCC group are discussed in a
critical manner (Hara et al, 1999). The authors found that the stan-
dard CD44 isoform (CD44s) is present in normal kidneys and in
most RCCs but the incidence of predominant expression of
CD44(v8-v10) in high-stage RCC is significantly higher than that
in low-stage RCC. In paraffin-embedded tumour tissues the
CD44(v6) variant sequence was detected in 2 out of 91 (Paradis
et al, 1999) and in 6 out of 27 samples (Heider et al, 1996). 
Since CD44 mainly mediates cell attachment to extracellular
matrix components (especially to hyaluronat, HA) and to HA-
bearing cells the importance of CD44 modulation by alternative
splicing could be in a higher stage of progression rather than in the
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Figure 3 uPA activity determined in cell monolayers by HPLC. Each value
represents the AMC released after 40 min substrate reaction at 37˚C. The
AMC peak areas obtained by HPLC were used for quantification. CMK 
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phospholipase C (preincubation: 1 h, 37˚C, PBS pH 7.4) 
Figure 4 APN activity assay. o-Ph: 1, 10-phenanthroline. The final
concentrations of the inhibitors were: 1: 0.5 mM, 2: 1.5 mM, 3: 1.0 mM,
4: 2.0 mM
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initiation of RCC. Finally, in a late stage of carcinogenesis an
increased CD44 expression may allow tumour cells to attach more
tightly to HA in the target tissue promoting tumour cell implanta-
tion (Gilcrease et al, 1996; Penno and Hart, 1998). If results of
melanoma cells are to be included into this matter more complex
conditions are revealed for possible mechanisms. The dominant
features of highly aggressive melanoma cells compared to less
aggressive melanomas and melanocytes were: (1) the higher level
of CD44 epitope recognized by the mAb Hermes-1; (2) phospho-
rylation of the CD44 molecule; (3) a significantly higher rate of
CD44 synthesis; (4) shedding of CD44 from and secretion of HA
by the tumour cells (Goebeler et al, 1996). 
Unlike CD44 ICAM-1 mediates heterotypical cell–cell interac-
tions especially to cells bearing the lymphocyte function-related
antigen-1 (LFA-1). ICAM-1 may facilitate the attachment of
tumour cells to vascular endothelium following to invade the base-
ment membrane. Another effect of tumour cells expressing ICAM-
1 is the reduced interaction with lymphocytes by (1) decreased
expression of HLA class I molecules (major histocompatibility
complex), (2) secretion of immunsuppressive cytokines (e.g. inter-
leukin 10) and (3) release of soluble ICAM-1 that competes for its
receptor (LFA-1) on the lymphocyte to prevent the attachment via
membrane-bound ICAM-1. These features enable one to evade the
normal host immune response by the tumour cell. Cell surface
expression and shedding of ICAM-1 by RCCs is described on
stimulated cells (Hansen et al, 1994; Tanabe et al, 1997) and
unstimulated cells (Koga et al, 1997). 
uPA associated with tumour is described as a multifunctional
factor (Andreasen et al, 1997; Reuning et al, 1998). The standard
mechanism commonly accepted for receptor-bound uPA is the
release of plasmin from plasminogen and the following activation of
matrix metalloproteinases (MMPs) such as type IV pro-collagenase
by plasmin. Subsequently, plasmin as well as activated MMPs may
degrade ECM proteins facilitating invasion through tissue barriers
(Ellis and Dano, 1998). Investigation of 18 RCC tissue samples
revealed an uPA antigen content twice as much as compared with
normal kidney or tumour-adjacent tissue and the uPA-like activity
was triple that of normal control tissue (Kirchheimer et al, 1985).
Using immunohistochemistry and ELISA techniques uPA/uPAR
was analysed in 33 RCC tissue samples (Wagner et al, 1995). They
found that uPA is expressed at relatively low levels in RCCs
without significant difference to normal non-tumourous kidney
tissue. The authors explain the similar distribution of uPA in
tumourous and normal kidney tissue by the usually high endoge-
nous level in healthy kidney that may disguise uPA changes in
RCC. Without use of an uPA activity assay these authors were
unable to differentiate between enzymatically active uPA and inac-
tive pro-uPA in RCC. Secondly, a speculation was made to explain
the difference between the low uPA mRNA level and the distinctly
higher uPA protein level in RCC: uPA receptors on RCC cells are
capable of binding uPA molecules secreted from surrounding non-
tumour cells. On the other hand, a significantly higher expression
of all components of the uPA activation system (uPA, uPAR and
PAI-1) in kidney cancers compared with normal kidney tissue was
found using the ELISA technique (Swiercz et al, 1998). Another
investigation has shown the influence of different organs and their
fibroblasts on the production of uPA by human RCC cells
implanted in nude mice (Gohji et al, 1997). High levels of uPA
were produced by the metastatic kidney tumours and lung metas-
tases, whereas the subcutaneous tumours produced low levels.
RCC cells co-cultured with mouse kidney or lung fibroblasts
produced higher levels of uPA than tumour cells co-cultured with
mouse skin fibroblasts. These findings suggest that the expression
of uPA on tumour cells is influenced by surrounding non-tumour
cells and their secreted factors. 
On tumour cells uPA/uPAR is present at focal adhesion sites,
preferentially at the invasive front and in contact to substratum
(Andreasen et al, 1997), thus on adherent growing cells most of the
uPA/uPAR complex is hidden. Additionally, human melanoma
cells were shown to have an uPAR/uPA localization described as
present in caveolae, flask-shaped microinvaginations of the
plasma membrane (Stahl and Mueller, 1995). The negligible reac-
tivity of the PI-PLC (Figure 3) may be caused by the hidden local-
ization of the uPAR/uPA as well as the existence of a ‘screening’
glycocalyx (Koelsch et al, 1994). Extensive summaries of the role
of APN in tissue invasion and its adhesive ability on various
tumour cells were given (Nanus et al, 1997; Noren et al, 1997).
The detection of APN antigen as well as APN activity in RCCs
and RCC cells was described in detail (Saiki et al, 1993; Riemann
et al, 1995; Göhring et al, 1998). 
To summarize, additional to the proteolytic capacity of cells
expressing uPA/uPAR and APN some findings clearly show an
adhesive contribution of these cell surface proteins (Stahl and
Mueller, 1997; Reuning et al, 1998). This multifunctional capacity
of some cell surface proteins and their modulation suggests that
different tumour cells could exhibit a similar adhesive and
metastatic behaviour in spite of certain variations of the surface
antigen composition. Extensive immunophenotyping of tumour
cells including activity or functional tests could reveal whether a
low-expressed or absent protein(ase) could be replaced by another
equivalent functioning protein(ase). 
Examples mentioned above clearly show that a lot of factors
confer aggressive and metastatic behaviour to tumour cells. But
crucial regulatory mechanisms responsible for growth and metas-
tasis are still unclear. Investigations of more than one functional
component of a tumour cell in combination with activity or func-
tional tests should provide more insight into these complex
processes (Laube, 1999b; Yu and Stamenkovic, 1999). 
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